Spyre Therapeutics, Inc. (SYRE) Stock Price & Analysis
Spyre Therapeutics, Inc. (SYRE) rose 2.14% to USD 102.13 as of July 25, 2026 at 03:08 UTC, according to Nexqual real-time market data.
SYRE last closed at USD 99.99; the session ranged USD 98.79–103.57 on volume of 752,950 shares. Market capitalization is $8.87B, with a 52-week range of USD 14.51–105.09 (NMS). Source: Nexqual, July 25, 2026 at 03:08 UTC.
Key Statistics (as of July 25, 2026 at 03:08 UTC)
| Price | USD 102.13 |
|---|---|
| Change | ▲ 2.14% (up) |
| Previous Close | USD 99.99 |
| Open | USD 100.56 |
| Day Range | USD 98.79 – 103.57 |
| 52-Week Range | USD 14.51 – 105.09 |
| Volume | 752,950 shares |
| Market Cap | $8.87B |
| Exchange | NMS |
Technical Analysis (SYRE)
Nexqual's technical model rates SYRE "BUY" based on 5 bullish and 1 bearish signals across 125 daily candles, as of July 25, 2026 at 03:08 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 61.6 (neutral) |
| vs SMA50 | Above (USD 84.98) |
| MACD | 4.6 (positive) |
Analyst Ratings (SYRE)
Wall Street analysts rate SYRE "Strong Buy" based on 15 analysts, with a mean price target of USD 103.93 (range USD 78–135), per Nexqual as of July 25, 2026 at 03:08 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 15 |
| Mean Target | USD 103.93 |
| High Target | USD 135 |
| Low Target | USD 78 |
| Buy / Hold / Sell | 17 / 0 / 0 |
Earnings (SYRE)
| Next Earnings Date | 2026-08-04 |
|---|---|
| EPS Estimate | USD -0.75 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.74 vs est -0.65 ▼ miss |
| 2025-12-31 | USD -0.74 vs est -0.8 ▲ beat |
| 2025-09-30 | USD -0.15 vs est -0.74 ▲ beat |
| 2025-06-30 | USD -0.49 vs est -0.71 ▲ beat |
Source: Nexqual, July 25, 2026 at 03:08 UTC.
Financials & Fundamentals (SYRE)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -31.11% |
| Current Ratio | 8.97 |
| Total Cash | $741.47M |
| Total Debt | $0 |
| Free Cash Flow | $-75.52M |
Source: Nexqual, July 25, 2026 at 03:08 UTC.
Financial Health Score (SYRE)
Nexqual rates Spyre Therapeutics, Inc.'s overall financial health "Weak" across five dimensions, as of July 25, 2026 at 03:08 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Mixed — $741M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$186M |
| Efficiency | Critical — ROE -31%, ROA -22.6% |
Ownership (SYRE)
| Insider Ownership | +5.86% |
|---|---|
| Institutional Ownership | +93.35% |
| Shares Outstanding | 86.84M |
| Float | 81.05M |
| Short % of Float | +16.81% |
Source: Nexqual, July 25, 2026 at 03:08 UTC.
Leadership (SYRE)
Spyre Therapeutics, Inc. is led by Cameron Turtle DPHIL (age 35), CEO & Director, per Nexqual as of July 25, 2026 at 03:08 UTC.
| CEO & Director | Cameron Turtle DPHIL (age 35) |
|---|---|
| Chief Financial Officer | Scott L. Burrows (age 48) |
| Senior Vice President of Operations | Janet Gunzner-Toste |
| Senior Vice President of Finance & Investor Relations | Eric McIntyre |
| Senior Vice President of Quality & Compliance | James Myers |
Major Backers & Investors (SYRE)
Notable institutional backers of Spyre Therapeutics, Inc. include FMR, LLC, Fidelity, RTW Investments LP, according to Nexqual as of July 25, 2026 at 03:08 UTC.
Active Investors
| Investor | Stake |
|---|---|
| FMR, LLC | 13.4% |
| Fidelity | 5.64% |
| RTW Investments LP | 4.74% |
| Fairmount Funds Management LLC | 4.57% |
| Perceptive Advisors Llc | 4.3% |
| Venrock Adviser, LLC | 4.19% |
| Driehaus Capital Management, LLC | 3.17% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 8.31% |
| Vanguard Group | 6.87% |
| State Street | 4.46% |
Source: Nexqual, July 25, 2026 at 03:08 UTC.
From Spyre Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-02-19)
Key Strengths & Strategy (as disclosed to the SEC)
- We seek to protect our proprietary information, in part by executing confidentiality agreements with our collaborators and scientific advisors, and non-competition, non-solicitation, confidentiality and invention assignment agreements with our employees and consultants.
- The confidentiality agreements we enter into are designed to protect our proprietary information and the agreements or clauses requiring assignment of inventions to us are designed to grant us ownership of technologies that are developed through our relationship with the respective counterparty.
- Commercial Should any of our product candidates be approved for commercialization, we intend to develop a plan to commercialize them in the United States and other key markets, through internal infrastructure and/or external partnerships in a manner that will enable us to realize the full commercial value of our product candidates.
- Our manufacturing strategy enables us to more efficiently direct financial resources to the research, development and commercialization of programs rather than diverting resources to internally develop and maintain manufacturing facilities.
Partnerships
- With respect to the SPY002 License Agreement only, on a product by product basis, we are obligated to pay sublicensing fees of up to approximately $20 million upon the achievement of mostly commercial milestones.
- Paragon Agreement In May 2023, Pre-Merger Spyre entered into the Paragon Agreement with Paragon and Parapyre.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| DNTH | Dianthus Therapeutics, Inc. | USD 103.87 | ▲ 1.08% |
| ORKA | Oruka Therapeutics, Inc. | USD 92.16 | ▼ 0.4% |
| APGE | Apogee Therapeutics, Inc. | USD 134.28 | ▲ 0.15% |
| ELVN | Enliven Therapeutics, Inc. | USD 52.95 | ▲ 0.19% |
| CGON | CG Oncology, Inc. | USD 69.32 | ▲ 0.01% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 03:08 UTC. This page is informational and not investment advice.